U.S Protein Expression Systems Market size is anticipated to be valuated at USD 6.1 Billion by 2035; Chronic Disease Cases Drives Growth in Protein Expression Market

Download Sample

Published Date: May 2025

The U.S protein expression systems market that involves technologies for producing functional proteins in various host cells as such systems are crucial for applications in drug development, academic research and biotechnology. U.S. protein expression systems have large scale usage in producing therapeutic proteins, enzymes, and vaccines along with supporting structural biology, molecular biology and functional genomics in their research activities.

Segmentation Analysis:

By Product Type	Reagents, Expression Vectors/Plasmids, Competent Cells, and Instruments
System Type	Prokaryotic Expression Systems, Eukaryotic Expression Systems
Application	Therapeutic Protein Production, Research Applications, Industrial Enzymes, Diagnostics, and Others
By End-User	Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and Others

Report Highlights:

U.S protein expression systems market size is accounted for USD 2.2 Billion in 2025.
Target market size is estimated to be valuated at USD 6.1 Billion by 2035 and at a registered CAGR of 5.89 %.
By Product type, Reagents is the dominant product segment in the U.S protein expression systems market share
By Application, the therapeutic protein production segment is expected to influence the U.S protein expression systems market share.
By end-user, the pharmaceutical and biotechnology companies is the end user ruling over the U.S protein expression systems market share.

Market Dynamics:

Growing Factor

Challenge Factor

Market Trend

Chronic Disease Cases Drives Growth in Protein Expression Market

High Cost and Complex Eukaryotic Systems Limits Market Growth in U.S.

Advancement in biotechnology and expansion of biopharmaceutical R&D in Protein Expression Systems Gas Market

Key Highlights:

In October 2024, Phase I clinical trial of PRX-115 data was introduced by Protalix BioTherapeutics their recombinant PEGylated uricase product candidate was developed using their proprietary ProCellEx plant cell-based protein expression system.
In September 2024, a joint partnership with Novartis was announced by Generate: Biomedicines, which is a Cambridge, Massachusetts-based biotechnology company specializing in machine learning for protein design that aims to leverage Generate's generative AI platform to develop novel protein therapeutics, reflecting the growing integration of artificial intelligence in protein engineering and protein expression systems.

Report Analysis:

Trends in U.S Protein Expression Systems Market:

Advancement in biotechnology and expansion of biopharmaceutical R&D for enhancing the efficiency and yield of protein production for cost effective protein expression systems and further increasing the focus on extensive research and development activities in the biopharmaceutical sector for development of novel therapeutics by adopting protein expression technologies. Current trends include dominance of mammalian expression systems that is gaining prominence due to their ability to produce complex proteins for therapeutic applications.

Browse ∼70 market data tables and ∼55 figures through ∼170 slides and in-depth TOC on “U.S Protein Expression Systems Market, By Product Type (Reagents, Expression Vectors/Plasmids, Competent Cells, and Instruments), System Type (Prokaryotic Expression Systems, Eukaryotic Expression Systems), Application (Therapeutic Protein Production, Research Applications, Industrial Enzymes, Diagnostics, and Others), End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and Others), and Country - Trends, Analysis, and Forecast till 2035”

Segmentation:

By Product Type:

Reagents
Expression Vectors/Plasmids
Competent Cells
Instruments

By System Type

Prokaryotic Expression Systems
Eukaryotic Expression Systems

By Application:

Therapeutic Protein Production
Research Applications
Industrial Enzymes
Diagnostics
Others

By End User:

Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Contract Research Organizations (CROs)
Contract Manufacturing Organizations (CMOs)
Others

For more insights into the U.S Protein Expression Systems Market and its future trends, visit link below: https://www.prophecymarketinsights.com/market_insight/us-protein-expression-systems-market-5861

Competitive Landscape of U.S Protein Expression Systems Market:

The key players operating the U.S protein expression systems market include Agilent Technologies, Inc., Ajinomoto Bio-Pharma?, Lonza., Merck KGaA, New England Biolabs, GenScript, Sigma-Aldrich Chemicals Private Limited, SINO BIOLOGICAL, INC., Promega Corporation, Ajinomoto Bio-Pharma, Evitria AG, ProteoGenix, Bio-Techne, Ventria Bioscience Inc., and Boster Biological Technology.